• 1
    Andrews B.S., Eisenberg R.A., Theofilopoulos A.N. et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148, 1198.
  • 2
    Eisenberg R.A., Tan E.M., Dixon F.J. (1978) Presence of anti-Sm reactivity in autoimmune mouse strains. J Exp Med 147, 582.
  • 3
    Steinberg A.D., Klinman D.M., Kastner D.L. et al. (1978) Genetic and molecular genetic studies of murine and human lupus. J Rheumatol 14, 166.
  • 4
    Jonsson R., Tarkowski A., Backman K., Holmdahl R., Klareskog L. (1987) Sialadenitis in the MRL-l mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology 60, 611.
  • 5
    Watanabe-fuknaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314.
  • 6
    Chu J.L., Drappa J., Parnassa A., Eikon K.B. (1993) The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransponson, ETn. J Exp Med 178, 723.
  • 7
    Singer G.G. & Abbas A.K. (1994) The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365.
  • 8
    Renno T., Hahne M., Tschopp J., MacDonald H.R. (1996) Peripheral T cells undergoing superantigen-induced apoptosis in vivo expression B220 and upregulate Fas and Fas ligand. J Exp Med 183, 431.
  • 9
    Morse III H.C., Davidson W.F., Yetter R.A., Murphy E.D., Roths J.B., Coffman R.L. (1982) Abnormalities induced by the mutant gene lpr: expansion of a unique lymphocyte subset. J Immunol 129, 2612.
  • 10
    Cohen P.L. & Eisenberg R.A. (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9, 243.
  • 11
    Butta A., MacLennan K., Flanders K.C., Sacks N.P.M., Smith I., McKinna A. (1992) Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52, 4261.
  • 12
    Jordan V.C. (1993) Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110, 507.
  • 13
    Jordan V.C. (1995) Third annual William L. McGuire Memorial Lecture. Studies on the estrogen receptor in breast cancer – 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36, 267.
  • 14
    Nayfield S.G. (1995) Tamoxifen's role in chemoprevention of breast cancer: an update. J Cell Biochem 22 (Suppl.), 42.
  • 15
    Chakravarty N. (1992) The roles of carmodulin and protein kinase C in histamine secretion from mast cells. Agents Actions 36, 183.
  • 16
    Colletta A.A., Benson J.R., Michael B. (1994) Alternative mechanisms of action of anti-estrogens. Breast Cancer Res Treat 31, 5.
  • 17
    Wiseman H. (1994) Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 15, 83.
  • 18
    Knabbe C., Zugmaier G., Schmahl M. (1991) Induction to transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl. 2), S15.
  • 19
    Baral E., Nagy E., Berczi I. (1995) Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 75, 591.
  • 20
    Kang Y., Cortina R., Perry R.R. (1996) Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 88, 279.
  • 21
    O'brian C.A., Liskamp R.M., Soloman D.H., Weistein I.B. (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45, 2462.
  • 22
    Drach J., Gsur A., Hamilton G. et al. (1996) Involvement of p-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 88, 1747.
  • 23
    Lavie Y., Zhang Z.C., Cao H.T. et al. (1998) Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 77, 928.
  • 24
    Lφnning P.E., Hall K., Aakvaag A., Lien E.A. (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52, 4719.
  • 25
    Steinberg A.D., Roths J.B., Murphy D.E., Steinber R.T., Raveche E.S. (1980) Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol 125, 871.
  • 26
    Roubinian J.R., Talal N., Greenspan J.S., Goodman J.R., Siiteri P.K. (1978) Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/W F1 mice. J Exp Med 147, 1568.
  • 27
    Sthoeger Z.M., Bentwich Z., Zinger H., Mozes E. (1994) The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 21, 2231.
  • 28
    Dayan M., Zinger H., Kalush F. et al. (1997) The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 90, 101.
  • 29
    Ye Y.L., Chuang Y.H., Chiang B.L. (1996) In vitro and in vivo functional analysis of CD5+ and CD5 B cells of autoimmune NZB × NZW F1 mice. Clin Exp Immunol 106, 253.
  • 30
    Lin L.C., Chen Y.C., Chou C.C., Hsieh K.H., Chiang B.L. (1995) Dysregulation of T helper cell cytokines in autoimmune prone NZB × NZW F1 mice. Scand J Immunol 42, 466.
  • 31
    Chen Y.C., Ye Y.L., Chiang B.L. (1997) Establishment and characterization of cloned CD4 CD8αβTCR bearing autoreactive T cells from autoimmune NZB/W F1 mice . Clin Exp Immunol 108, 52.
  • 32
    Mitenyi S., Muller W., Weichel W., Radbruch A. (1990) High gradient magnetic cell separation with MACS. Cytometry 11, 231.
  • 33
    Kaplan E.L. & Meier P. (1958) Nonparametric estimation from incomplete observation. J Am Stat Ass 53, 457.
  • 34
    Izui S., Kelley V.E., Masuda K., Yoshida H., Roths J.B., Murphy E.D. (1984) Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 159, 2265.
  • 35
    Roubinian J., Talal N., Silter P.K., Sadakian J.A. (1979) Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheumatism 22, 1162.
  • 36
    Holmdahl R. (1989) Estrogen exaggerates lupus but suppresses T-cell dependent autoimmune disease. J Autoimmunity 2, 651.
  • 37
    Snapper C. & Mond J.J. (1993) Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1, 15.
  • 38
    Santoro T.J., Portanova J.P., Kotzin B.L. (1988) The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice . J Exp Med 167, 1713.
  • 39
    Koh D.R., Ho A., Rahemtulla A., Fung-leung W.P., Griesser H., Mak T.W. (1995) Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 25, 2558.
  • 40
    Wofsy D., Hardy R.R., Seaman W.E. (1984) The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on ‘helper’ T cells that is involved in the response to class II major histocompatibility antigens. J Immunol 132, 2686.
  • 41
    Altman A., Theofilopoulos A.N., Weiner R., Katz D.H., Dixon F.J. (1981) Analysis of T cells function in autoimmune murine strains: Defects in production and responsiveness to interleukin-2. J Exp Med 154, 791.
  • 42
    Liang H.E., Hsueh Y.P., Wu C.C., Hsu S.C., Han S.H., Lai M.Z. (1998) Atypical signal defects prevent IL-2 gene expression in lpr/lpr CD4 CD8 cells. J Biomed Sci 5, 297.
  • 43
    Radvanyi L.G., Raju K., Spaner D., Mills G.B., Miller R.G. (1998) Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cell Immunol 183, 1.